MA47607A - Synthèse à grande échelle d'arn messager - Google Patents
Synthèse à grande échelle d'arn messagerInfo
- Publication number
- MA47607A MA47607A MA047607A MA47607A MA47607A MA 47607 A MA47607 A MA 47607A MA 047607 A MA047607 A MA 047607A MA 47607 A MA47607 A MA 47607A MA 47607 A MA47607 A MA 47607A
- Authority
- MA
- Morocco
- Prior art keywords
- arn
- messenger
- scale synthesis
- synthesis
- scale
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44773—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis
- G01N27/44778—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis on a common gel carrier, i.e. 2D gel electrophoresis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Electrochemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Dispersion Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464043P | 2017-02-27 | 2017-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47607A true MA47607A (fr) | 2020-01-01 |
Family
ID=61800667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047607A MA47607A (fr) | 2017-02-27 | 2018-02-27 | Synthèse à grande échelle d'arn messager |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11560562B2 (fr) |
| EP (2) | EP4105326A1 (fr) |
| AU (2) | AU2018224325B2 (fr) |
| CA (1) | CA3053814A1 (fr) |
| DK (1) | DK3585886T5 (fr) |
| ES (1) | ES2971902T3 (fr) |
| HU (1) | HUE065140T2 (fr) |
| IL (2) | IL310939B2 (fr) |
| MA (1) | MA47607A (fr) |
| WO (1) | WO2018157153A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3998064A1 (fr) | 2011-06-08 | 2022-05-18 | Translate Bio, Inc. | Lipides clivables |
| JP7423522B2 (ja) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド |
| WO2021127641A1 (fr) | 2019-12-20 | 2021-06-24 | Translate Bio, Inc. | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
| IL294073A (en) | 2019-12-20 | 2022-08-01 | Translate Bio Inc | Rectal administration of messenger rna |
| EP4103712A1 (fr) | 2020-02-10 | 2022-12-21 | Translate Bio, Inc. | Procédés et compositions pour purification d'arn messager |
| CN115398546A (zh) | 2020-02-18 | 2022-11-25 | 翻译生物公司 | 用于信使rna体外转录的改进方法 |
| US11969480B2 (en) | 2020-02-25 | 2024-04-30 | Translate Bio, Inc. | Processes of preparing mRNA-loaded lipid nanoparticles |
| WO2021226436A1 (fr) | 2020-05-07 | 2021-11-11 | Translate Bio, Inc. | Séquences nucléotidiques optimisées codant pour des antigènes du sras-cov-2 |
| EP4146680A1 (fr) | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Composition et méthodes de traitement d'une dyskinésie ciliaire primitive |
| WO2021231901A1 (fr) | 2020-05-15 | 2021-11-18 | Translate Bio, Inc. | Formulations de nanoparticules lipidiques pour l'administration d'arnm |
| JP2023544197A (ja) | 2020-10-06 | 2023-10-20 | トランスレイト バイオ， インコーポレイテッド | 脂質ナノ粒子の改善された方法および製剤 |
| US20220133631A1 (en) | 2020-10-12 | 2022-05-05 | Translate Bio, Inc. | Process of preparing ice-based lipid nanoparticles |
| WO2022081544A1 (fr) | 2020-10-12 | 2022-04-21 | Translate Bio, Inc. | Procédé amélioré de préparation de nanoparticules lipidiques chargées d'arnm |
| EP4229208A4 (fr) | 2020-10-14 | 2024-10-30 | George Mason Research Foundation, Inc. | Méthodes de fabrication de nanoparticules lipidiques et compositions dérivées de celles-ci |
| US20220136022A1 (en) * | 2020-10-15 | 2022-05-05 | Translate Bio, Inc. | Large Scale Synthesis of Messenger RNA |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| US20250268994A1 (en) | 2021-03-25 | 2025-08-28 | Translate Bio, Inc. | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof |
| JP2024515668A (ja) | 2021-04-19 | 2024-04-10 | トランスレイト バイオ， インコーポレイテッド | Ｍｒｎａの送達のための改善された組成物 |
| EP4362920A1 (fr) | 2021-07-01 | 2024-05-08 | Translate Bio, Inc. | Compositions de livraison d'arnm |
| WO2023086893A1 (fr) | 2021-11-10 | 2023-05-19 | Translate Bio, Inc. | Composition et méthodes de traitement de la dyskinésie ciliaire primitive |
| CA3258428A1 (fr) * | 2022-07-01 | 2024-01-04 | Arcturus Therapeutics, Inc. | Méthodes améliorées de transcription in vitro |
| IL318619A (en) | 2022-07-29 | 2025-03-01 | Sanofi Pasteur Inc | Methods for ethanol-free purification of mRNA |
| WO2024112652A1 (fr) | 2022-11-21 | 2024-05-30 | Translate Bio, Inc. | Compositions de formulations de poudre sèche d'arn messager et leurs procédés d'utilisation |
| AU2023394992A1 (en) | 2022-12-15 | 2025-07-31 | Sanofi Pasteur Inc. | Mrna encoding influenza virus-like particle |
| AR131438A1 (es) | 2022-12-20 | 2025-03-19 | Sanofi Sa | VACUNA DE ARNm DE RINOVIRUS |
| WO2024133884A2 (fr) | 2022-12-23 | 2024-06-27 | Sanofi | Queue optimisée d'arn messager |
| WO2024141784A2 (fr) | 2022-12-29 | 2024-07-04 | Popvax Private Limited | Vaccins et compositions à protection large contre les bètacoronavirus |
| WO2024141786A2 (fr) | 2022-12-29 | 2024-07-04 | Popvax Private Limited | Vaccins et agents thérapeutiques multicibles |
| WO2024184489A1 (fr) | 2023-03-07 | 2024-09-12 | Sanofi | Fabrication d'arn messager avec kp34 polymérase |
| EP4698156A1 (fr) | 2023-04-17 | 2026-02-25 | Sanofi Pasteur Inc. | Formulations de poudre sèche reconstituables et leurs procédés d'utilisation |
| WO2025017151A1 (fr) | 2023-07-18 | 2025-01-23 | Sanofi | Matrices d'arn messager codant pour le poly(a) stables |
| WO2025104351A1 (fr) | 2023-11-17 | 2025-05-22 | Sanofi Pasteur Inc. | Dosages par clhp pour détecter de multiples constructions d'arnm |
| WO2026033123A1 (fr) | 2024-08-08 | 2026-02-12 | Sanofi Pasteur Inc. | Formulations de nanoparticules lipidiques pour l'administration d'arnm |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| WO2009030254A1 (fr) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes d'arn et de peptides cationiques pour transfection et immunostimulation |
| BR112012002291A2 (pt) | 2009-07-31 | 2016-11-29 | Ethris Gmbh | "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos" |
| US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
| ME03091B (fr) | 2009-12-01 | 2019-01-20 | Translate Bio Inc | Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| WO2014152659A1 (fr) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Évaluation quantitative pour l'efficacité de coiffage de l'arn messager |
| KR20150128687A (ko) | 2013-03-14 | 2015-11-18 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna의 정제 방법 |
| KR102739894B1 (ko) | 2014-04-25 | 2024-12-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| SG11201608605QA (en) * | 2014-06-10 | 2016-12-29 | Curevac Ag | Methods and means for enhancing rna production |
| US10172924B2 (en) * | 2015-03-19 | 2019-01-08 | Translate Bio, Inc. | MRNA therapy for pompe disease |
| EP3294885B1 (fr) * | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Procédé de production d'arn |
| MX2019010155A (es) * | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
-
2018
- 2018-02-27 EP EP22169158.7A patent/EP4105326A1/fr active Pending
- 2018-02-27 CA CA3053814A patent/CA3053814A1/fr active Pending
- 2018-02-27 WO PCT/US2018/020008 patent/WO2018157153A1/fr not_active Ceased
- 2018-02-27 IL IL310939A patent/IL310939B2/en unknown
- 2018-02-27 US US15/907,163 patent/US11560562B2/en active Active
- 2018-02-27 MA MA047607A patent/MA47607A/fr unknown
- 2018-02-27 HU HUE18713747A patent/HUE065140T2/hu unknown
- 2018-02-27 IL IL268892A patent/IL268892B2/en unknown
- 2018-02-27 AU AU2018224325A patent/AU2018224325B2/en active Active
- 2018-02-27 DK DK18713747.6T patent/DK3585886T5/da active
- 2018-02-27 ES ES18713747T patent/ES2971902T3/es active Active
- 2018-02-27 EP EP18713747.6A patent/EP3585886B1/fr active Active
-
2022
- 2022-12-14 US US18/065,952 patent/US20240018514A1/en active Pending
-
2024
- 2024-07-31 AU AU2024205244A patent/AU2024205244A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018224325A1 (en) | 2019-09-12 |
| HUE065140T2 (hu) | 2024-05-28 |
| EP3585886A1 (fr) | 2020-01-01 |
| IL268892B1 (en) | 2024-03-01 |
| IL310939B2 (en) | 2026-01-01 |
| WO2018157153A1 (fr) | 2018-08-30 |
| AU2018224325B2 (en) | 2024-05-02 |
| IL268892B2 (en) | 2024-07-01 |
| US20180258423A1 (en) | 2018-09-13 |
| DK3585886T5 (da) | 2024-09-02 |
| US11560562B2 (en) | 2023-01-24 |
| EP4105326A1 (fr) | 2022-12-21 |
| AU2024205244A1 (en) | 2024-08-22 |
| DK3585886T3 (da) | 2024-02-19 |
| ES2971902T3 (es) | 2024-06-10 |
| IL310939B1 (en) | 2025-09-01 |
| CA3053814A1 (fr) | 2018-08-30 |
| EP3585886B1 (fr) | 2023-11-22 |
| US20240018514A1 (en) | 2024-01-18 |
| IL310939A (en) | 2024-04-01 |
| IL268892A (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47607A (fr) | Synthèse à grande échelle d'arn messager | |
| EP3658885A4 (fr) | Tube d'isolement | |
| EP3796668A4 (fr) | Écouteur | |
| EP3607587A4 (fr) | Panneau d'affichage | |
| EP3703672A4 (fr) | Formulations à base de cannabinoïdes | |
| MA49421A (fr) | Formulations d'arn | |
| IL266212A (en) | Direction for arrival assessment | |
| EP3341861A4 (fr) | Recommandation de vidéos d'après des titres de vidéos | |
| EP3587557A4 (fr) | Micro-organisme isolé de larve detenebrio | |
| MA46761A (fr) | Administration sous-cutanée d'arn messager | |
| EP3696336A4 (fr) | Structure d'assemblage pour poutre en h | |
| EP3394754A4 (fr) | Planification d'applications fortement parallèles | |
| EP3448417A4 (fr) | Conjugués dimères d'insuline-incrétine | |
| EP3658683A4 (fr) | Découverte d'épitopes à médiation par trogocytose | |
| EP3506254A4 (fr) | Structure d'insonorisation | |
| EP3377981A4 (fr) | Planification des ressources d'un instrument | |
| EP3799594A4 (fr) | Production d'oligosaccharides | |
| EP3525479A4 (fr) | Casque d'écoute | |
| EP3598705A4 (fr) | Commande d'acheminement | |
| EP3467761A4 (fr) | Serveur d'envoi de corbillard | |
| EP3612516A4 (fr) | Synthèse de mésotrione | |
| MA53238A (fr) | Formules d'ag10 | |
| MA42690A (fr) | Micropropagation d'un dattier abada | |
| EP3761922C0 (fr) | Support d'épaule orthétique | |
| EP3720268A4 (fr) | Cultivar de stévia '16228013' |